Your browser doesn't support javascript.
loading
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature.
Visintin, Alberto; Knowlton, Kelly; Tyminski, Edyta; Lin, Chi-Iou; Zheng, Xiang; Marquette, Kimberly; Jain, Sadhana; Tchistiakova, Lioudmila; Li, Dan; O'Donnell, Christopher J; Maderna, Andreas; Cao, Xianjun; Dunn, Robert; Snyder, William B; Abraham, Anson K; Leal, Mauricio; Shetty, Shoba; Barry, Anthony; Zawel, Leigh; Coyle, Anthony J; Dvorak, Harold F; Jaminet, Shou-Ching.
Afiliação
  • Visintin A; Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
  • Knowlton K; Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
  • Tyminski E; Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
  • Lin CI; The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts.
  • Zheng X; Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
  • Marquette K; Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts.
  • Jain S; Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts.
  • Tchistiakova L; Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts.
  • Li D; The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts.
  • O'Donnell CJ; Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut.
  • Maderna A; Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut.
  • Cao X; Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California.
  • Dunn R; Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California.
  • Snyder WB; Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California.
  • Abraham AK; Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
  • Leal M; Pfizer Inc., Pharmacokinetics, Dynamics and Metabolism (PDM), Pearl River, New York.
  • Shetty S; Pfizer Inc., Drug Safety R&D, Investigative Toxicology, Groton, Connecticut.
  • Barry A; Pfizer Inc., Biotherapeutics Pharmaceutical Sciences, Andover, Massachusetts.
  • Zawel L; Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
  • Coyle AJ; Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts.
  • Dvorak HF; The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts. sjaminet@bidmc.harvard.edu hdvorak@bidmc.harvard.edu.
  • Jaminet SC; The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts. sjaminet@bidmc.harvard.edu hdvorak@bidmc.harvard.edu.
Mol Cancer Ther ; 14(8): 1868-76, 2015 Aug.
Article em En | MEDLINE | ID: mdl-26089370
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Angiogênese / Anticorpos Monoclonais / Proteínas de Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Angiogênese / Anticorpos Monoclonais / Proteínas de Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article